Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Oncogene ; 43(21): 1644-1653, 2024 May.
Article in English | MEDLINE | ID: mdl-38594504

ABSTRACT

Ferroptosis has been demonstrated a promising way to counteract chemoresistance of multiple myeloma (MM), however, roles and mechanism of bone marrow stromal cells (BMSCs) in regulating ferroptosis of MM cells remain elusive. Here, we uncovered that MM cells were more susceptible to ferroptotic induction under the interaction of BMSCs using in vitro and in vivo models. Mechanistically, BMSCs elevated the iron level in MM cells, thereby activating the steroid biosynthesis pathway, especially the production of lanosterol, a major source of reactive oxygen species (ROS) in MM cells. We discovered that direct coupling of CD40 ligand and CD40 receptor constituted the key signaling pathway governing lanosterol biosynthesis, and disruption of CD40/CD40L interaction using an anti-CD40 neutralizing antibody or conditional depletion of Cd40l in BMSCs successfully eliminated the iron level and lanosterol production of MM cells localized in the Vk*MYC Vk12653 or NSG mouse models. Our study deciphers the mechanism of BMSCs dictating ferroptosis of MM cells and highlights the therapeutic potential of non-apoptosis strategies for managing refractory or relapsed MM patients.


Subject(s)
Ferroptosis , Lanosterol , Mesenchymal Stem Cells , Multiple Myeloma , Multiple Myeloma/pathology , Multiple Myeloma/metabolism , Animals , Lanosterol/pharmacology , Humans , Mice , Mesenchymal Stem Cells/metabolism , Reactive Oxygen Species/metabolism , Cell Line, Tumor , Iron/metabolism , Signal Transduction
2.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi ; 41(3): 317-321, 2024 Mar 10.
Article in Chinese | MEDLINE | ID: mdl-38448021

ABSTRACT

OBJECTIVE: To explore the genetic basis for a Chinese pedigree and a sporadic case with Neurofibromatosis type 1 (NF1). METHODS: Clinical data of the pedigree and the sporadic case were collected. Genomic DNA was extracted from peripheral venous blood samples and subjected to whole exome sequencing. Candidate variants were validated by Sanger sequencing and bioinformatic analysis. RESULTS: All patients from the pedigree were found to harbor a c.3251delC variant in exon 25 of the NF1 gene, whilst a c.4312_4314delGAA variant was found in exon 32 of the NF1 gene in the sporadic case. CONCLUSION: Variants of the NF1 gene may account for the occurrence of NF1 in this pedigree and sporadic case.


Subject(s)
Blood Group Antigens , Neurofibromatosis 1 , Humans , Asian People/genetics , China , Genes, Neurofibromatosis 1 , Neurofibromatosis 1/genetics , Pedigree
3.
World J Clin Cases ; 11(25): 6000-6004, 2023 Sep 06.
Article in English | MEDLINE | ID: mdl-37727473

ABSTRACT

BACKGROUND: The mixed lineage leukemia (MLL)-eleven-nineteen lysine-rich leukemia (ELL) fusion gene is a rare occurrence among the various MLL fusion genes. We present the first case in which myeloid sarcoma (MS) was the only manifestation of adult MLL-ELL-positive acute myeloid leukemia (AML). CASE SUMMARY: We report a case of a 33-year-old male patient who was admitted in June 2022 with a right occipital area mass measuring approximately 7 cm × 8 cm. Blood work was normal. The patient underwent right occipital giant subscalp mass excision and incisional flap grafting. Immunohistochemistry was positive for myeloperoxidase, CD43 and CD45 and negative for CD3, CD20, CD34, and CD56. The bone marrow aspirate showed hypercellularity with 20% myeloblasts. Flow cytometry showed that myeloblasts accounted for 27.21% of the nucleated cells, which expressed CD33, CD38, and CD117. The karyotype was 46, XY, t (11, 19) (q23; p13.1), -12, + mar/46, XY. Next-generation sequencing showed a fusion of MLL exon 7 to exon 2 of ELL. A diagnosis of MLL-ELL-positive AML (M2 subtype) with subcutaneous MS was made. CONCLUSION: MLL-ELL-positive AML with MS is a rare clinical entity. Additional research is needed to elucidate the molecular mechanisms of the pathogenesis of MS.

4.
Transl Oncol ; 37: 101765, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37619524

ABSTRACT

Easily developed chemoresistance is a major characteristic of multiple myeloma (MM) and the main obstacle in curing MM in the clinic, but the key regulators have not been fully identified. In the current study, we find that PPFIA Binding Protein 1 (PPFIBP1) is highly expressed in the plasma cells from MM patients, and higher PPFIBP1 expression predicts poorer outcomes. PPFPIBP1 enhances chemoresistance of MM cells to the treatment of bortezomib (BTZ), a proteasome inhibitor, and manipulation of PPFPIBP1 can alter chemosensitivity of MM cells to BTZ. Mechanistic studies reveal that PPFPIBP1 directly binds and stabilizes RelA, promotes the cyto-nuclear translocation of RelA, and activates NF-κB signaling pathway. Targeting PPFPIBP1 in a xenograft mouse model of MM prohibits tumor growth and prolongs overall survival of mice. Taken together, our findings suggest that PPFIBP1 is a crucial regulator of chemoresistance to PIs in MM cells, and shed light on developing therapeutic strategies to overcome chemoresistance by targeting PPFIBP1.

5.
Cancer Med ; 12(17): 17766-17775, 2023 09.
Article in English | MEDLINE | ID: mdl-37584196

ABSTRACT

BACKGROUND: The innovative combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has established a new chapter of curative approach in acute promyelocytic leukemia (APL). The disease characteristics and prognostic influence of additional cytogenetic abnormalities (ACA) in APL with modern therapeutic strategy need to be elucidated. METHODS: In the present study, we retrospectively investigated disease features and prognostic power of ACA in 171 APL patients treated with ATRA-ATO-containing regimens. RESULTS: Patients with ACA had markedly decreased hemoglobin levels than that without ACA (p = 0.021). Risk stratification in the ACA group was significantly worse than that in the non-ACA group (p = 0.032). With a median follow-up period of 62.0 months, worse event-free survival (EFS) was demonstrated in patients harboring ACA. Multivariate analysis showed that ACA was an independent adverse factor for EFS (p = 0.033). By further subgroup analysis, in CD34 and CD56 negative APL, patients harboring ACA had inferior EFS (p = 0.017; p = 0.037). CONCLUSIONS: To sum up, ACA remains the independent prognostic value for EFS, we should build risk-adapted therapeutic strategies in the long-term management of APL when such abnormalities are detected.


Subject(s)
Arsenicals , Leukemia, Promyelocytic, Acute , Humans , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/genetics , Progression-Free Survival , Retrospective Studies , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Tretinoin/therapeutic use , Chromosome Aberrations , Oxides/therapeutic use , Arsenicals/therapeutic use , Treatment Outcome
6.
Platelets ; 34(1): 2176167, 2023 Dec.
Article in English | MEDLINE | ID: mdl-36786035

ABSTRACT

Essential thrombocythemia (ET) with double driver mutations is a rare disease. ET patients with both MPL and Type 1 CALR mutations have been reported. Here, we report the first case of an ET patient with both MPL S204P and Type 2 CALR mutations and a summary of our literature review findings. In the patient whose case is reported here, the disease progressed to an accelerated phase 3.5 months after diagnosis. CALR mutation disappeared and new mutations emerged as the disease progressed, such as ASXL1, CBL, ETV6, and PTPN11 mutations. This case highlights that screening for additional mutations using NGS should be considered in patients with ET to assess the prognosis, especially as the disease progresses.


Subject(s)
Myeloproliferative Disorders , Thrombocythemia, Essential , Humans , Thrombocythemia, Essential/complications , Thrombocythemia, Essential/diagnosis , Thrombocythemia, Essential/genetics , Calreticulin/genetics , Janus Kinase 2/genetics , Mutation , Clonal Evolution , Genomics , Receptors, Thrombopoietin/genetics
7.
Front Oncol ; 12: 871115, 2022.
Article in English | MEDLINE | ID: mdl-35880163

ABSTRACT

Our study is a retrospective medical record review performed on 95 female keloid patients with the standard therapy combining complete surgical excision with superficial X-ray radiation. We aimed to analyze the relationship between breast size and treatment outcomes as well as the benefits of sports bras in the postoperative management of keloids. The results showed that the keloid score of no sports bra group was significantly worse than the score of sports bra group at 1-year follow-up. In addition, the large breast size group showed more significant improvement of keloid score when wearing sports bras. Our study highlights that continuous wearing a sports bra effectively reduces the skin tension of the postoperative incision and promotes recovery, especially for patients with large breast size.

8.
Carcinogenesis ; 42(10): 1223-1231, 2021 10 26.
Article in English | MEDLINE | ID: mdl-34546340

ABSTRACT

Bortezomib-based chemotherapy represents the most prevalent regimens for multiple myeloma (MM), whereas acquired drug resistance remains a major obstacle. Myeloma cells often produce excessive amount of dickkopf-1 (DKK1), giving rise to myeloma bone disease. However, it remains obscure about the effects and mechanisms of DKK1 in the progression and bortezomib responsiveness of MM cells. In the current study, we found WWP2, an E3 ubiquitin-protein ligase, was downregulated in the bortezomib-resistant cells along with high expression of DKK1. Further investigation revealed that WWP2 was a direct target of Wnt/ß-catenin signaling pathway, and DKK1 suppressed the expression of WWP2 via canonical Wnt signaling. We further identified that WWP2 mediated the ubiquitination and degradation of GLI2, a main transcriptional factor of the Hedgehog (Hh) pathway. Therefore, DKK1-induced WWP2 downregulation improved GLI2 stability and activation of Hh signaling pathway, contributing to the resistance to bortezomib of MM cells. Clinical data also validated that WWP2 expression was associated with the treatment response and clinic outcomes of MM patients. WWP2 overexpression restricted MM progression and enhanced cell sensitivity to bortezomib treatment in vitro and in vivo. Taken together, our findings demonstrate that DKK1 facilitates the generation of bortezomib resistance in MM via downregulating WWP2 and activating Hh pathway. Thus, the manipulation of DKK1-WWP2-GLI2 axis might sensitize myeloma cells to proteasome inhibitors.


Subject(s)
Antineoplastic Agents/therapeutic use , Bortezomib/therapeutic use , Drug Resistance, Neoplasm/physiology , Intercellular Signaling Peptides and Proteins/physiology , Multiple Myeloma/drug therapy , Nuclear Proteins/metabolism , Ubiquitin-Protein Ligases/genetics , Zinc Finger Protein Gli2/metabolism , Cell Line, Tumor , HEK293 Cells , Humans , Multiple Myeloma/metabolism , Treatment Outcome , Ubiquitin-Protein Ligases/physiology , Ubiquitination , Wnt Signaling Pathway
9.
Front Genet ; 12: 705038, 2021.
Article in English | MEDLINE | ID: mdl-34267784

ABSTRACT

Characterization and identification of recombination hotspots provide important insights into the mechanism of recombination and genome evolution. In contrast with existing sequence-based models for predicting recombination hotspots which were defined in a ORF-based manner, here, we first defined recombination hot/cold spots based on public high-resolution Spo11-oligo-seq data, then characterized them in terms of DNA sequence and epigenetic marks, and finally presented classifiers to identify hotspots. We found that, in addition to some previously discovered DNA-based features like GC-skew, recombination hotspots in yeast can also be characterized by some remarkable features associated with DNA physical properties and shape. More importantly, by using DNA-based features and several epigenetic marks, we built several classifiers to discriminate hotspots from coldspots, and found that SVM classifier performs the best with an accuracy of ∼92%, which is also the highest among the models in comparison. Feature importance analysis combined with prediction results show that epigenetic marks and variation of sequence-based features along the hotspots contribute dominantly to hotspot identification. By using incremental feature selection method, an optimal feature subset that consists of much less features was obtained without sacrificing prediction accuracy.

10.
Environ Monit Assess ; 193(8): 483, 2021 Jul 09.
Article in English | MEDLINE | ID: mdl-34241745

ABSTRACT

This work investigated heavy metal and cyanide pollution in surface soils and edible plants around Yanzhuang gold tailings ponds in the region of Yanzhuang Village in Pinggu District, Beijing. Surface soil samples were collected from 33 sites around gold tailings ponds, and concentrations of seven heavy metals (i.e., Sb, As, Cd, Cu, Pb, Zn, and Hg) and cyanide were analyzed to determine their spatial distributions, pollution degrees, and sources. The potential ecological risks of As, Cd, Cu, Pb, Zn, and Hg were preliminarily assessed. The results showed that the mean cyanide, Sb, As, Cd, Cu, and Pb concentrations were higher than the standard values. The pollutant concentrations around the tailings ponds were high and decreased with increasing distance from the ponds. The single pollution index indicated that cyanide, As, and Cd were the main pollutants. The Nemerow pollution index revealed a large region and serious degree of heavy metal pollution in soils. The potential ecological risk level of the study area was moderate, with Cd and As posing the main risks. Multivariate statistical analysis suggested that the heavy metal and cyanide pollution present mainly derived from gold tailings, with agricultural pollution also had a certain effect. However, the 12 edible plants sampled were basically not polluted.


Subject(s)
Environmental Pollutants , Metals, Heavy , Soil Pollutants , Beijing , China , Environmental Monitoring , Gold , Metals, Heavy/analysis , Ponds , Risk Assessment , Soil , Soil Pollutants/analysis
11.
Nat Commun ; 12(1): 1022, 2021 02 15.
Article in English | MEDLINE | ID: mdl-33589584

ABSTRACT

Development of chemoresistance is the main reason for failure of clinical management of multiple myeloma (MM), but the genetic and epigenetic aberrations that interact to confer such chemoresistance remains unknown. In the present study, we find that high steroid receptor coactivator-3 (SRC-3) expression is correlated with relapse/refractory and poor outcomes in MM patients treated with bortezomib (BTZ)-based regimens. Furthermore, in immortalized cell lines, high SRC-3 enhances resistance to proteasome inhibitor (PI)-induced apoptosis. Overexpressed histone methyltransferase NSD2 in patients bearing a t(4;14) translocation or in BTZ-resistant MM cells coordinates elevated SRC-3 by enhancing its liquid-liquid phase separation to supranormally modify histone H3 lysine 36 dimethylation (H3K36me2) modifications on promoters of anti-apoptotic genes. Targeting SRC-3 or interference of its interactions with NSD2 using a newly developed inhibitor, SI-2, sensitizes BTZ treatment and overcomes drug resistance both in vitro and in vivo. Taken together, our findings elucidate a previously unrecognized orchestration of SRC-3 and NSD2 in acquired drug resistance of MM and suggest that SI-2 may be efficacious for overcoming drug resistance in MM patients.


Subject(s)
Drug Resistance, Neoplasm/drug effects , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Neoplastic , Histone-Lysine N-Methyltransferase/genetics , Multiple Myeloma/drug therapy , Nuclear Receptor Coactivator 3/genetics , Repressor Proteins/genetics , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis/genetics , Bone and Bones/drug effects , Bone and Bones/metabolism , Bone and Bones/pathology , Bortezomib/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 4 , Drug Resistance, Neoplasm/genetics , Female , Histone-Lysine N-Methyltransferase/metabolism , Histones/genetics , Histones/metabolism , Humans , Male , Middle Aged , Multiple Myeloma/genetics , Multiple Myeloma/mortality , Multiple Myeloma/pathology , Nuclear Receptor Coactivator 3/antagonists & inhibitors , Nuclear Receptor Coactivator 3/metabolism , Proteasome Inhibitors/pharmacology , Recurrence , Repressor Proteins/metabolism , Signal Transduction , Survival Analysis , Translocation, Genetic , Xenograft Model Antitumor Assays
13.
Oncogene ; 39(4): 922-934, 2020 01.
Article in English | MEDLINE | ID: mdl-31576013

ABSTRACT

Multiple myeloma (MM) is still incurable despite the successful application of proteasome inhibitors in clinic. Bortezomib represents the most common chemotherapy for MM, whereas acquired drug resistance and eventually developed relapse remain the major obstruction. In the current study, we established bortezomib-resistant myeloma cell lines and screened gene expression profiles using single cell RNA-sequencing. Resistant MM cells exhibited increased clonogenic potential, specific metabolic, and epigenetic signatures, along with the self-renewal signaling characteristic of MM stem-like cells. Aberrant activation of hedgehog (Hh) signaling was correlated with drug resistance and stem cell-like transcriptional program. The key transcriptional factor GLI2 of the Hh pathway was restricted in the high acetylation and low ubiquitination states in bortezomib-resistant myeloma cells. Further investigation revealed that SIRT1 deacetylates and stabilizes GLI2 protein at lysine 757 and consequentially activates the Hh signaling, and itself serves as a direct target of Hh signaling to format a positive regulating loop. Using combination screening with an epigenetic compound library, we identified the SIRT1 specific inhibitor S1541 and S2804 had very obvious synergetic antimyeloma effect. Sirt1 inhibition could partially impeded the Hh pathway and conferred bortezomib sensitivity in vitro and in vivo. Notably, elevated SIRT1 level was also a prominent hallmark for the resistant myeloma cells, and this expression pattern was confirmed in myeloma patients, but independent of RAS/RAF mutations. Clinically, SIRT1 expression in patients with complete response was suppressed but elevated in relapsed patients, and retrospective analysis showed patients with higher SIRT1 expression had poorer outcomes. In conclusion, the cooperation of SIRT1 and Hh is an important mechanism of drug resistance in myeloma, and therapeutics combining SIRT1 inhibitors will sensitize myeloma cells to proteasome inhibitors.


Subject(s)
Bortezomib/pharmacology , Drug Resistance, Neoplasm , Hedgehog Proteins , Multiple Myeloma/drug therapy , Nuclear Proteins/metabolism , Proteasome Inhibitors/pharmacology , Sirtuin 1/metabolism , Zinc Finger Protein Gli2/metabolism , Aged , Aged, 80 and over , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Mice , Mice, Inbred NOD , Mice, SCID , Middle Aged , Molecular Targeted Therapy , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Nuclear Proteins/genetics , Signal Transduction , Sirtuin 1/antagonists & inhibitors , Sirtuin 1/genetics , Zinc Finger Protein Gli2/genetics
14.
Hematology ; 24(1): 455-458, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31076019

ABSTRACT

Objectives and importance: Chronic neutrophilic leukemia (CNL) is a distinct myeloproliferative neoplasm with a high prevalence (>80%) of mutations in the colony-stimulating factor 3 receptor (CSF3R); these mutations activate the receptor, leading to the proliferation of neutrophils that are a hallmark of CNL. Clinical presentation: We present a male patient who presented peripheral blood leukocytosis. On the basis of his morphological appearances and molecular findings he was determined to have a diagnosis of chronic neutrophilic leukemia. At a follow-up at 7 months, in addition to the CSF3R c.2373G > A (p.W791*) truncated mutation, another CSF3R mutation appeared as c.1853C > T(p.T618I). Discussion and conclusion: We present the first patient with a diagnosis of chronic neutrophilic leukemia with a c.2373G > A (p.W791*) truncated mutation of CSF3R. These findings elucidate a novel paradigm of CNL pathogenesis and explain how mutations drive the development of the disease. The order of acquisition of CSF3R mutations relative to mutations in epigenetic modifiers and the spliceosome have been determined only in isolated case reports; thus, further work is needed to understand the impact of mutation chronology on the clonal evolution and progression of CNL.


Subject(s)
Clonal Evolution/genetics , Leukemia, Neutrophilic, Chronic/genetics , Aged , Humans , Male
15.
Transl Cancer Res ; 8(5): 2121-2129, 2019 Sep.
Article in English | MEDLINE | ID: mdl-35116962

ABSTRACT

BACKGROUND: Tumor cells are surrounded by many inflammatory cells, including mast cells (MCs), which can secrete several classic proangiogenic factors, resulting in endothelial cell proliferation and angiogenesis. However, the researches of the number of MC and microvessel density (MVD) in the bone marrow in chronic myeloid leukemia (CML) are rare. In this study, we aimed to investigate the relationship between tryptase-positive MCs and MVD in the different phases of CML. METHODS: Bone marrow samples of 61 patients with CML and 20 healthy donors were collected from 2007 to 2017. Antibodies against the endothelial cell marker CD34 and against tryptase were used in immunohistochemistry. The diagnosis and counting of tryptase-positive MC and microvessel in bone marrow was at ×400 magnification. RESULTS: MVD in CML group was higher than which in the control group, and the blast phase (BP) group had a higher MVD than which in chronic phase (CP) group (P<0.05). The number of MCs in three groups of CML was higher than which in control group, and the number of MCs in AMLT group was highest (P<0.05). Patients with a lower grade of tryptase-positive MCs in CP group survived longer OS and PFS (P<0.05). CONCLUSIONS: The number of MCs and MVD might be markers for the outcome of patients with CML in the Chinese population.

16.
Arch Dermatol Res ; 310(7): 561-566, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29931443

ABSTRACT

Keloids are skin fibroproliferative tumors characterized by locally invasive growth of fibroblasts and excessive collagen deposition. The objective of this study is to investigate the molecular basis of the keloid scar by studying the mutation of related genes. We performed gene screening of mechanoreceptors by quantitative polymerase chain reaction (qPCR), Sanger sequencing to detect the CXCR1gene mutation, and immuno-histochemistry to determine CXCR1 protein expression. Among the genes encoding mechanoreceptors, the expression of CXCR1 mRNA was significantly higher in keloid scar tissues than in the surrounding tissues of normal controls (P < 0.05). Sequencing analysis identified a novel missense mutation, c.574G > A (p.Gly192Glu). Immunohistochemistry showed heightened protein expression of CXCR1 in keloid scars as compared to controls. Our findings indicate that CXCR1 gene mutation and altered protein expression are associated with keloid scar development. Identification of the CXCR1 gene mutation might provide insights into the molecular mechanism underlying keloid scar and underscores the potential importance of mechanoreceptors in keloid scar pathogenesis.


Subject(s)
Cicatrix, Hypertrophic/genetics , Keloid/genetics , Mutation, Missense/genetics , RNA, Messenger/genetics , Receptors, Interleukin-8A/genetics , Skin/pathology , China , Cicatrix, Hypertrophic/metabolism , Female , Genetic Testing , Humans , Immunohistochemistry , Keloid/metabolism , Male , Mechanoreceptors/metabolism , Receptors, Interleukin-8A/metabolism , Retrospective Studies , Skin/metabolism , Up-Regulation
17.
Oncotarget ; 8(39): 65609-65619, 2017 Sep 12.
Article in English | MEDLINE | ID: mdl-29029457

ABSTRACT

Primary bone lymphomas (PBLs) are composed of malignant lymphoid cells presenting in osseous sites, without supra-regional lymph node or extranodal involvement. We systematically characterized the immunophenotype and the myeloid differentiation factor 88 (MYD88)-L265P gene mutation status in PBL. Clinical data from 19 patients with PBL treated at Nanjing Drum Tower Hospital between 2009 and 2015 were analyzed retrospectively. Protein expression patterns were identified immunohistochemically, and MYD88 mutation was assessed using polymerase chain reaction and direct DNA sequencing. Fifteen patients presented with diffuse large B-cell lymphoma. Clinical factors favoring a good prognosis were an age < 60 years and rituximab treatment. B-cell lymphoma 2 expression was detected in 5/15 diffuse large B-cell lymphoma patients, and was associated with a poor prognosis in a univariate model. Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling factors were upregulated in PBLs. All eighteen evaluable PBL samples harbored wild-type MYD88. These data thus suggest that age and rituximab treatment are independent prognostic factors determining overall survival, and that activation of JAK/STAT3 signaling may promote the pathogenesis of PBL. Moreover, the absence of MYD88-L265P mutation in PBL indicate there are distinct pathogenetic backgrounds among extranodal lymphomas.

18.
Oncotarget ; 8(6): 9708-9716, 2017 Feb 07.
Article in English | MEDLINE | ID: mdl-28039454

ABSTRACT

PURPOSE: We estimated the expression of nuclear factor kappa B/p65 in non-germinal center B-cell-like subtype diffuse large B-cell lymphoma, to investigate its relationship to clinicopathological features, and to further evaluate its prognostic value and clarify its impact on survival. RESULTS: Among the 49 patients enrolled in this study, 14 (28.6%) had positive p65 expression. The negative p65 group had significantly better survival compared to the positive p65 group in terms of both the 3-year estimated OS (91.2% vs. 39.3%, p = 0.003) and PFS (75.6% vs. 26.5%, p = 0.002). In patients with 4 or more risk factors, p65 was an independent prognostic factor of OS (HR 5.99, 95%CI=1.39-25.75, p=0.016) and PFS (HR 4.01, 95%CI=1.15-14.00, p=0.029). MATERIALS AND METHODS: The expression of the NF-κB/p65 protein was deteremined by immunohistochemistry in 49 non-GCB DLBCL. Survival was assessed by the Kaplan-Meier method and Cox multivariate analysis. The median patient follow-up period was 24 months. CONCLUSIONS: The expression of NF-κB/p65 has prognostic value in high risk non-GCB DLBCL, and it is a suitable target for the development of new therapies.


Subject(s)
Biomarkers, Tumor/analysis , Lymphoma, Large B-Cell, Diffuse/chemistry , Transcription Factor RelA/analysis , Adolescent , Adult , Aged , Disease-Free Survival , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Proportional Hazards Models , Retrospective Studies , Risk Factors , Time Factors , Young Adult
19.
Medicine (Baltimore) ; 96(51): e9451, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29390580

ABSTRACT

RATIONALE: Hemophagocytic lymphohistiocytosis (HLH) secondary to methicillin-resistant Staphylococcus epidermidis (MRSE)-related left-sided infectious endocarditis had never been reported before. In the last decade, daptomycin, a novel lipopeptide antibiotic, showed its excellent role in anti-Gram-positive bacteria, including soft tissue infection, bloodstream and deep tissueinfection. PATIENT CONCERNS: An Asian women under sever condition due to the cooccurrence of HLH and MRSE-related endocarditis while also be allergic to vancomycin. The patient was cured by high-dose daptomycin monotheraphy, HLH-2004 protocol and cardiothoracic surgery to remove the valve at last, and was obviously benefit from the endeavor of a multidisciplinary team (MDT) strategy. DIAGNOSES: IE was made on March 27according to the modified Duke criteria. HLH was diagnosed too. INTERVENTIONS: The patient was cured by high-dose daptomycin monotheraphy, HLH-2004 protocol and cardiothoracic surgery to remove the valve at last, and was obviously benefit from the endeavor of a multidisciplinary team (MDT) strategy. OUTCOMES: The patient was healthy andstable when we published this case. LESSONS: This case proves high-dose daptomycin monotheraphy could be used as an effective alternative regimen for vancomycin in treating MRSE-related left-sided endocarditis and highlight the importance of early diagnosis and appropriate management for HLH. Furthermore, our work suggests an MDT model as a practical strategy in managing similar clinical situation.


Subject(s)
Endocarditis, Bacterial/complications , Lymphohistiocytosis, Hemophagocytic/complications , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/complications , Adult , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Daptomycin/therapeutic use , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/surgery , Endocarditis, Bacterial/therapy , Female , Humans , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/microbiology , Staphylococcal Infections/microbiology
20.
Hematology ; 22(3): 145-148, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27875935

ABSTRACT

BACKGROUND: Mutations in Janus kinase 2 (JAK2), myeloproliferative leukemia (MPL), and CALR are highly relevant to Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms. METHODS: Assessing the prevalence of molecular mutations in Chinese Han patients with essential thrombocythemia (ET), and correlating their mutational profile with disease characteristics/phenotype. RESULTS: Of the 110 subjects studied, 62 carried the JAK2 V617F mutation, 21 had CALR mutations, one carried an MPL (W515) mutation, and 28 had non-mutated JAK2, CALR, and MPL (so-called triple-negative ET). Mutations in JAK2 exon 12 were not detected in any patient. Two ET patients had both CALR and JAK2 V617F mutations. Comparing the hematological parameters of the patients with JAK2 mutations with those of the patients with CALR mutations showed that the ET patients with CALR mutations were younger (p = 0.045) and had higher platelet counts (p = 0.043). CONCLUSION: Genotyping for CALR could be a useful diagnostic tool for JAK2/MPL-negative ET, since the data suggest that CALR is much more prevalent than MPL, therefore testing for CALR should be considered in patients who are JAK2 negative as its frequency is almost 20 times that of MPL mutation.


Subject(s)
Asian People/genetics , Calreticulin/genetics , Janus Kinase 2/genetics , Mutation , Receptors, Thrombopoietin/genetics , Thrombocythemia, Essential/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , China , DNA Mutational Analysis , Female , Humans , Male , Middle Aged , Phenotype , Retrospective Studies , Thrombocythemia, Essential/diagnosis , Thrombocythemia, Essential/drug therapy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...